Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

February 25, 2021 2:23 AM UTC

ICON plc (NASDAQ:ICLR) is buying fellow CRO PRA Health Sciences Inc. (NASDAQ:PRAH) in a cash and stock transaction valued at about $12 billion. The deal combines ICON’s Accellacare site network, home health services and wearables expertise with PRA’s mobile and connected health platforms and real-world data and information services. ICON CEO Steve Cutler will be CEO of the combined company, which will be based in Dublin.

Yisheng to deploy megaround to expand facilities, speed vaccine development
Yisheng Biopharma Co. Ltd. raised $130 million in a series B round co-led by Oceanpine and OrbiMed Advisors. The Beijing-based cancer and infectious disease company will use the funds in part to expand its R&D center and accelerate clinical development of multiple vaccines and the construction of biologics production facilities in China and Singapore...